Covid-19 roundup: Albert Bourla says Pfizer PhIII is at 23,000 patients, submission coming end of October
Months ago, public health officials thought it could take several months to prove a vaccine works. Even when continually high coronavirus case counts in the US made trials easier to run, there was still concern about how quickly companies would be able to enroll volunteers.
On Thursday, though, Pfizer CEO Albert Bourla disclosed that, as of yesterday, Pfizer had reached 23,000 volunteers in the Phase III trial for their mRNA Covid-19 vaccine, a “significant number” of whom have already gotten the second dose. That would put Pfizer and their partner BioNTech just 7,000 patients short of their target and, Bourla said, in line to give an update on efficacy by the end of October.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.